ALEXION NMO · ALXN1210-NMO-307
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A phase 3, multicenter, open-label, externally placebo-controlled study evaluating the efficacy and safety of ravulizumab in adults with neuromyelitis optica spectrum disorder (NMOSD). EudraCT: 2019-003352-37.
Sponsor: ALEXION
Phase: III
Area: Neuroimmunology